Patent · US Active

Polynucleotides encoding GDNFRα

US7691606B2 · kind B2 · utility

1Cited by
2References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 20, 2006
Grant dateApr 6, 2010
Priority date
Expiry dateFeb 20, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

GDNFRα, GDNFRα extracellular domain (ECD), GDNFRα variants, chimeric GDNFRα (e.g., GDNFRα immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFRα-ligands, for example GDNF, by providing GDNFRα to the cell. Also provided are methods for using GDNFRα, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.